Search This Blog

Saturday, October 3, 2026

Ukraine Wants Humanoid Robots for Most Dangerous Front-Line Jobs, for as Little as $10,000 Apiece

The robot Ukraine’s former defense minister wants to send to war would look at least somewhat human; at least, in function.

Mykhailo Fedorov, a 35-year-old politician and technology entrepreneur who previously oversaw Ukraine’s rapid expansion of battlefield drones as defense minister, is now trying to do something similar with terrestrial robots. His goal is to build relatively simple, humanoid machines that can perform jobs soldiers still have to do themselves: reload a machine gun, swap batteries in sensors, launch drones and operate in places where sending a person could be deadly. On the front line under constant 24/7 video surveillance, a soldier can be spotted and swiftly attacked with a drone in mere minutes, and that is not an exaggeration.

At the IT Arena technology conference in Lviv on Sept. 26, Fedorov called for a “new Manhattan Project” to accelerate military robotics. His new initiative, the Army of Robots, aims to bring engineers, startups, investors and military units together to develop such machines quickly enough to matter in the current war.

“Our idea is to combine engineers, startups and capital into one ecosystem so we can launch humanoid-like robots on the battlefield,” Fedorov told Defense News. “We want to eventually substitute our infantry with these robots.”

To be clear, Fedorov is not proposing anything like the fancy and polished general-purpose humanoids demonstrated by American and Chinese robotics companies. He says Ukraine needs simpler machines that can be manufactured cheaply, assigned a narrow set of battlefield tasks and produced in large numbers. In other words, we won’t see anything like in The Terminator anytime soon, at least not in Ukraine, but the concern is real that we’re heading in that direction.

To some of you reading about all this, the vision may sound a bit like a pipedream. After all, Ukraine is one of the poorest countries in Europe. However, it would be a mistake to underestimate them, as Vladimir Putin and his army have painfully come to realize.

Ukraine is not starting from zero. Its forces already use ground robots for logistics, evacuation, mine operations and attacks. Fedorov now wants to move beyond mostly remote-controlled vehicles toward machines capable of performing some of the physical work that still keeps infantry soldiers on the front line.

From rolling supply carts to robot soldiers

Ukraine has rapidly expanded its use of unmanned ground vehicles, or UGVs, for jobs including carrying ammunition, evacuating wounded soldiers, laying mines and attacking positions.

In August alone, Ukrainian forces recorded more than 25,000 logistics and evacuation missions using ground robotic systems, 3.3 times as many as in January, according to figures released by Ukraine’s Defense Ministry.

But calling these machines “robots” can give the wrong impression. Most are essentially rugged remote-controlled vehicles. A human operator remains in charge, often steering the machine from kilometers away.

Ukraine has experimented with combat robots before. In late 2024, the Khartiia Brigade said it carried out what it described as the war’s first documented machine-only ground assault, combining armed vehicles with mine-laying and mine-clearing robots while drones watched from above. Reuters reported at the time that human infantry still advanced afterward to secure the area, and Reuters could not independently verify the brigade’s claim.

Fedorov wants to push much further.

According to Ukrainska Pravda, he has set a six-month goal for a humanoid robot to kill a Russian soldier and a 12-month goal for robots and drones to conduct an operation together without infantry taking on its most dangerous stages.

In a recent interview with Forbes Ukraine, Fedorov claimed that the first humanoid-like prototype could appear within a month. Current versions may cost roughly $40,000 to $70,000 each, Fedorov said, but mass deployment would require bringing that down to around $10,000 to $20,000.

“We are moving away from the types of humanoids we see in the United States toward simple models that can be scaled,” Fedorov told Forbes Ukraine.

Those figures sound like they are missing some zeros, but Ukraine does not need a robot that can cook dinner, climb stairs and fold laundry. It needs machines that can reliably perform a handful of specific actions under mud, jamming, gunfire and damaged communications.

Drone playbook moves onto the ground

Fedorov is trying to repeat a strategy Ukraine has already used with drones: encourage many small manufacturers, test their machines quickly with soldiers, measure what works and rapidly manufacture successful designs. There would be dozens of proposed products, but the competitive environment would incentivize the most cost-effective solution.

Ukraine’s Defense Ministry said in June that 95 percent of the drones procured through its defense purchasing agency were domestically manufactured. And they make over six million a year, of various classes, from the famous FPV drones that swarm the battlefield to the medium- and long-range strike drones that are more like precision munitions with wings and a noisy diesel rotary engine.

Ground robots are actually much harder to engineer than aerial drones. They must cross trenches, rubble and mud, carry substantial loads, survive electronic warfare and continue operating when communications fail. Humanoid machines add another layer of difficulty, such as maintaining balance. A wheeled robot can remain useful even if it is crude. A two-legged machine that falls over may need a soldier to rescue it — defeating much of the point.

That helps explain why Fedorov describes the proposed machines as “humanoid-like” rather than insisting on science-fiction-like androids. Not even he knows exactly what they’re going to look like, regardless of his CGI promo videos shared on social media.

There’s also the elephant in the room. How much decision-making should eventually pass from operator to machine? Surely, such robots will be equipped with sensors and computer vision; at some point, the incentive structure is such that a super-effective killer humanoid robot equipped with autonomous AI would be too tempting not to use. The other side will then be forced to respond in kind.

For now, Ukraine’s ground systems remain overwhelmingly human-controlled. But the Army of Robots explicitly includes autonomous systems and AI. In August, the United Nations and International Committee of the Red Cross renewed their call for international rules governing autonomous weapons, warning about systems that can select and attack targets without further human intervention. But does anyone pretend to care what the U.N. has to say?

Fedorov’s immediate argument is that Ukraine is fighting a larger opponent while fighting an existential war. In order to keep fighting, they need to conserve their precious few soldiers from being exposed to an increasingly drone-saturated battlefield.

“We don’t have enough time,” he told Defense News. “We need to achieve these results as soon as possible.”

https://www.zmescience.com/science/news-science/ukraine-humanoid-robot-initiative/

New weight-loss drug could give ‘flatter stomach’ in weeks — unlike Ozempic, targets belly fat directly

 Could a new drug that makes fat cells self-destruct be the next big GLP-1?

CBL-514 targets fat cells, and a new study shows it was effective in slimming down participants’ waistlines.

Early data suggests it’s effective at keeping it off, too.

hile GLP-1s mostly decrease fat, they also shed up to 25% vital lean mass. And after stopping GLP-1s, people often regain two-thirds of the weight they lost within a year.

“We expect that patients will be pleased by the cosmetic effects, such as the flatter stomach that can come with subcutaneous fat loss,” one author said.

“But it is the reduction in body weight, loss of visceral fat and the improvements in blood pressure, cholesterol and the like that should be associated with this that will be important for health.”

Some experts say CBL-514 could turn out to be “a more fundamental obesity therapy” than GLP-1 drugs like Ozempic.

What is CBL-514?

Like many GLP-1s, CBL-514 is an injectable drug. But rather than slowing digestion and decreasing appetite like GLP-1s, the new drug works more locally.

It blocks a critical way for fat cells to survive, causing them to die off at the injection site: the belly.

New data from Phase 2 clinical trials shows the drug reduces subcutaneous fat (fat right below the skin) and visceral fat (fat deep inside the body that wraps around the organs). Visceral fat, in particular, is a driver for conditions such as diabetes and cardiometabolic issues including heart attacks and strokes.

Common surgeries targeting subcutaneous fat, such as liposuction and abdominoplasty (aka a “tummy tuck”), are far more invasive, CBL-514 researchers say. These surgeries also introduce risks far worse than an uneven cosmetic result, including infections, blood vessel blockages, embolisms and even an internal organ being punctured.

CBL-514 works on both kinds of fat without the invasive surgery.

“This is a highly innovative approach to obesity pharmacotherapy that has produced some remarkable results in early human trials,” said Dr. W. Timothy Garvey, an adviser to Caliway, the drugmaker behind CBL-514, and a professor at University of Alabama at Birmingham.

What the latest data shows

In the latest trials, participants got a shot of CBL-514 every three weeks. The number of shots they got depended on the thickness of their belly fat, which decreased as the drug’s effects took hold.

After just four weeks, average visceral abdominal fat already decreased by 12%. A total of eight weeks after medication, fat was still 10.45% lower than at the start.

Researchers believe that once those fat cells are killed off, their ability to grow back is limited, making it difficult to regain the weight.

Right now, CBL-514’s lasting effects after medication is stopped have only been shown in rats, and researchers are looking into whether the effect can be replicated in humans.

Researchers are also exploring whether CBL-514 could work with a GLP-1 drug to help a patient stop taking it while reducing the risk of weight regain.

Other than “mostly mild-to-moderate and transient” injection-site reactions, such as pain, swelling and redness, CBL-514 was generally well tolerated, researchers said. No serious adverse events were reported.

The drug is now entering Phase 3 drug trials, the final stage before FDA approval.

https://nypost.com/2026/10/02/health/new-weight-loss-drug-targets-belly-fat-and-can-give-flatter-stomach-in-weeks/

GLP-1 use is way up in a key new-mom demographic — rates are 24x higher than in 2018

 This year, the number of US adults on a GLP-1 medication for weight loss reached an astonishing 11% — meaning more than one in 10 adults are on one form or another of the jab.

This explosion in use of drugs like Ozempic, Wegovy and Mounjaro has happened over a very short time — about five years — despite the drugs being on the market for over two decades.

People are on it because it works. Patients lose, on average, 7 to 11% of their starting weight. There’s also a number of unexpected benefits of being on the drug, from lowering risk of depression and potentially preventing dementia, to lowering risk of cancer, heart attack, and even substance abuse.

Still, people are mainly on it to shed pounds — including one demographic in particular, whose use of the drug has skyrocketed from .8% in 2018 to 1.9% in 2025 — a 24-fold increase.

They are new mothers, specifically women who get on the drug within six months of giving birth, new research found.

This research sheds new light on the larger demographic differences in GLP-1 use. Women use GLP-1s much more than men overall, making up as much as 70% of patients on the drug.

New moms on the jab

Researchers in this new study looked at 1 million births and tracked which moms started on GLP-1s within half a year.

They found that within the group, new moms with type 2 diabetes got the most prescriptions (increasing from 2.3% to 16.9%, or about one in six patients) between 2018 and 2025.

But those who had gestational diabetes — temporary diabetes that develops during pregnancy — also increased GLP-1 scripts dramatically, from .4 in 2021 to 2.7% in 2025.

Gestational diabetes happens in 5% to 9% of pregnancies in the US and gives a strong indication mom will develop diabetes later in life. As many as 50-70% of women who have gestational diabetes develop type 2 diabetes later.

The fastest increase, however, was among women diagnosed as obese or overweight before pregnancy. Their GLP-1 scripts jumped from from 0.4% in 2021 to 3.9% in 2025 — nearly a tenfold increase.

This touches on one of the biggest reasons overall GLP-1 use has exploded in recent years. GLP-1s weren’t always approved for weight loss — it was mainly used to help people with diabetes manage their blood sugar. But in 2021 that changed, opening the door to people who struggled with weight and obesity, kickstarting the frenzy we’re seeing now.

Losing pregnancy weight

Authors note that like gestational diabetes potentially causing problems down the road, weight gained during pregnancy can be hard to lose long after birth.

Twelve months after birth, up to 75% of women weigh more than they did before pregnancy. This extra weight contributes to issues with blood pressure, cholesterol, and insulin resistance.

One study even suggests that keeping the weight on one year after birth is an indicator they’ll weigh more 15 years down the line.

GLP-1s are generally avoided during pregnancy though, which helps explain why use skyrockets within six months after birth. Authors of the new study note it can be an important medication to manage long term risks associated with weight retention and diabetes.

However, given that moms are starting so soon after giving birth, authors are calling for more research on how GLP-1s might affect breastfeeding. One study showed that GLP-1s were not detectable in breast milk, but experts still advise caution and many do not advise using the drug while breastfeeding.

https://nypost.com/2026/10/03/health/glp-1-use-skyrocketed-24x-in-a-key-demographic/

'Iran-Iraq flights to resume Sunday'

 Flights between Iran and Iraq will resume on Sunday using both Iranian and Iraqi airlines, Iran's Civil Aviation Organization Head Abuzar Shiroudi said, according to IRNA.

"Based on the decisions taken at the level of the high authorities of the two countries, it was decided that flights between Iran and Iraq will be resumed by Iranian and Iraqi airlines starting tomorrow," Shiroudi said. He urged passengers to confirm flight times through official airline or airport channels before traveling.

Iraq's Najaf International Airport suspended all flights to and from Iran on September 25 until further notice. Tehran also recently canceled flights to the United Arab Emirates after several regional countries restricted Iranian airlines from using their airspace.

https://breakingthenews.net/Article/Iran-Iraq-flights-to-resume-Sunday/67228370

Second tanker explosion reported in Strait of Hormuz

 cond explosion involving an oil tanker was reported in the Strait of Hormuz on Saturday, with a commercial vessel heading toward Oman reportedly targeted, according to Fars News Agency.

Fars identified the vessel as the "Or Vinst" and claimed it switched off its tracking system after entering the strait under United States escort. It added on X that the Greek tanker "Athenagoras" was also leaving Oman and entering the Persian Gulf without transmitting a tracking signal.

The agency cited "The Hormuz Report" as claiming Iran had begun targeting vessels escorted by the US Navy. Earlier, Mehr News Agency stated explosions near Iran's Qeshm Island, saying the sounds appeared linked to activity in the Persian Gulf and Strait of Hormuz. The reports came after Axios said senior US officials, including Vice President JD Vance, held an unannounced Camp David meeting on Friday to discuss Iran and Yemen.

https://breakingthenews.net/Article/Second-tanker-explosion-reported-in-Strait-of-Hormuz/67228334

'Far-Left Riots "Tearing France Apart" Is Political Gift For Le Pen As Election Odds Soar'

 Riots that French officials blame on far-left groups have morphed into a political crisis, leaving hundreds injured and more than 100 high schools severely damaged. The social unrest appears to be a gift to right-wing presidential contender Marine Le Pen, whose Polymarket odds of winning next year's election have surged in recent days.

At least 65 school employees, including 40 principals, and roughly 170 students have been injured since the unrest began, Euronews reported Friday. Education Minister Édouard Geffray said at least 100 high schools had suffered severe damage.

The unrest began over overcrowded classrooms, teacher shortages, long school days, and deteriorating facilities. The government's proposed 2027 budget only offers a 1.7% increase in education spending, bringing the total to 65.53 billion euros.

French intelligence agencies told a government crisis meeting Thursday that radical politicians from the far-left France Unbowed party, known as LFI, had sparked the riots.

According to local outlet Le Monde, Geffray told reporters that far-left groups had taken control of the movement.

The broader security concern is that far-left groups exploit legitimate grievances, recruit younger and younger participants, and transform localized protests into opportunities to riot. The far-left-fueled riots that accompanied US protests in 2020 offer a cautionary tale about how these groups hijack movements, and Western governments are only now coming to their senses about this problem.

For Le Pen, these riots seem like a gift, as her Polymarket odds of winning next April's election have surged.

https://www.zerohedge.com/political/far-left-riots-tearing-france-apart-political-gift-le-pen-election-odds-soar

29 health systems affected by Oracle Health data breach

 Dozens of hospitals have had their patient data compromised by a 2025 breach of Oracle Health’s legacy Cerner systems.

Health systems continue to alert patients of the hack that occurred as early as Jan. 22, 2025. Oracle Health asked healthcare organizations to delay notification amid the investigation. The EHR vendor faces legal action over the incident.

Here are the hospitals and health systems that have reportedly been affected by the data breach, as of Oct. 1, 2026:

— Oaklawn Hospital (Marshall, Mich.)

— Great River Health (West Burlington, Iowa)

— Concord (N.H.) Hospital Health System

— Cabell Huntington (W.Va.) Hospital

— Huntsville (Ala.) Hospital Health System

— Marshall Health Network (Huntington, W.Va.)

— MultiCare Yakima (Wash.) Memorial Hospital

— Sharp Tri-City Medical Center (Oceanside, Calif.)

— Arkansas Heart Hospital (Little Rock)

— Albany (N.Y.) Med Health System

— Huntington Hospital (Pasadena, Calif.)

— Christus Health (Irving, Texas)

— Munson Healthcare (Traverse City, Mich.)

— Atrium Health (Charlotte, N.C.)

— Jupiter (Fla.) Medical Center

— AdventHealth (Altamonte Springs, Fla.)

— Aultman Health System (Canton, Ohio)

— Lake Regional Health System (Osage Beach, Mo.)

— OSF HealthCare (Peoria, Ill.)

— Hamilton (Ga.) Medical Center

— Methodist Le Bonheur Healthcare (Memphis, Tenn.)

— ChristianaCare (Newark, Del.)

— North Kansas City (Mo.) Hospital

— LifeBridge Health (Baltimore)

— Glens Falls (N.Y.) Hospital

— Baptist Health South Florida (Coral Gables)

— Mosaic Life Care (St. Joseph, Mo.)

— Tallahassee (Fla.) Memorial Healthcare

— Union Health (Terre Haute, Ind.)

https://www.beckershospitalreview.com/healthcare-information-technology/ehrs/29-health-systems-affected-by-oracle-health-data-breach/